Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine, irinotecan plus bevacizmab for metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Oxaliplatin 130mg/m2 day1 Capecitabin 2000mg/m2/day day1-15 Primary outcome(s): ORR;Over response rate Study Design: Single arm Non-randomized
创建时间：
2012-04-15
